An application of a transcription factor Spl specific inhibitor in preparation of medicines treating uveal melanoma

A technology of transcription factor and melanoma, which is applied in the application field of preparing drugs for treating uveal melanoma, can solve the problems of unclear efficacy and mechanism of action of uveal melanoma, and achieves improving the effectiveness of treatment, inhibiting cell growth, promoting effect of apoptosis

Active Publication Date: 2018-06-15
SHANGHAI NINTH PEOPLES HOSPITAL SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

But so far, there is no report on the application of transcription factor Spl-specific inhibitors in uveal melanoma drugs, and the curative effect and mechanism of action of uveal melanoma are still unclear

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • An application of a transcription factor Spl specific inhibitor in preparation of medicines treating uveal melanoma
  • An application of a transcription factor Spl specific inhibitor in preparation of medicines treating uveal melanoma
  • An application of a transcription factor Spl specific inhibitor in preparation of medicines treating uveal melanoma

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0015] IC50 determination experiment

[0016] Experimental procedure: OCM1 and OM431 cells were seeded in a 384-well plate, 2500 cells per well, 50ul culture medium, 10 concentration gradients were added to Mithramycin, 37°C, 5% CO 2 After incubating for 72 hours, add cell-title glo reagent and incubate at room temperature for 10 minutes, test on the computer, and calculate IC50 according to the measured experimental results, that is, the median lethal dose. Experimental results such as figure 1 shown.

Embodiment 2

[0018] Plate cloning experiments

[0019] Experimental procedure: OCM1 and OM431 cells were seeded in 6-well plates, 1000 cells per well, 2ml of culture medium, 10uM concentration of Mithramycin was added, 37°C, 5% CO 2 After culturing for 7 days, stained with crystal violet, the experimental results are as follows: figure 2 shown. Such as figure 2 Mithramycin can effectively inhibit the proliferation of uveal melanoma cells.

[0020] The present invention finds for the first time that the application of mithermycin in the preparation of drugs for uveal melanoma can significantly inhibit the growth and migration of uveal melanoma cells, and promote cell apoptosis, which provides a new therapeutic drug that can improve Treatment effectiveness, prolong life of patients, improve quality of life. Unprecedented to open up a new field.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

An application of a transcription factor Spl specific inhibitor in preparation of medicines treating uveal melanoma is disclosed. The molecular formula of the inhibitor is C<52>H<76>O<24>, and the molecular structural formula of the inhibitor is shown as a formula I shown in the description. The application of mithramycin in preparation of medicines treating uveal melanoma is disclosed for the first time. The mithramycin can significantly inhibit growth and migration of uveal melanoma cells and can promote cell apoptosis. A novel treatment medicine is provided and can improve treatment effectiveness, prolong lifetime of patients and improve life quality. An unprecedented novel field is opened up.

Description

technical field [0001] The invention relates to the field of medicine, in particular to the application of a specific inhibitor of transcription factor Sp1 in the preparation of a drug for treating uveal melanoma. Background technique [0002] Uveal melanoma (UM) is a special type of melanoma that originates from the uveal layer of the eye. UM is the most common primary intraocular malignancy in adults, the majority of which are choroidal melanomas. UM usually occurs unilaterally and unifocally, but rare cases of bilateral or multifocal tumors occur in the same eye. UM can not only cause vision loss, but also seriously threaten the life of patients. UM mainly metastasizes through blood, and half of the patients can develop distant metastases, mainly to the liver. Once the diagnosis is established, it is usually fatal within 1 year, because there is currently no effective clinical treatment. Even if the eyeball of the affected eye is removed before definite metastasis occ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/704A61P35/00
CPCA61K31/704
Inventor 张赫范先群李瑾王茜林明葛盛芳贾仁兵丁侠曹媛
Owner SHANGHAI NINTH PEOPLES HOSPITAL SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap